

ASX Release

EMvision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

PRE-QUOTATION DISCLOSURES

Emvision Medical Devices Limited (Company) confirms that the Offer by the Company pursuant to the prospectus dated 11 October 2018 (Prospectus) has now closed and the issue of 24,000,000 ordinary fully paid shares at an issue price of \$0.25 per share completed.

The following information is required to be provided to ASX Limited (ASX) for release to the market in connection with the admission of the Company to the official list and quotation of its fully paid ordinary shares.

Capitalised terms which have not otherwise been defined in this document have the same meaning as they have in the Prospectus.

Confirmation of Satisfaction of Licence Agreement and IP Assignment Deed Conditions Precedent

As set out in Section 9.3 of the Prospectus, the Company entered into a Licence Agreement and IP Assignment Deed with UniQuest Pty Ltd (Uniquet), whereby UniQuest licensed and then subsequently assigns the Licensed IP to the Company upon satisfaction of a number of conditions precedent.

The Company confirms that the conditions precedent under the Licence Agreement between the Company and Uniquet dated 13 September 2017 and varied by deeds of variation have been satisfied.

Confirmation of Issue of Options under Lead Manager Mandate

The Company confirms it has issued 2,000,000 Options, each exercisable at \$0.35 each and expiring on, or before, 31 December 2021 pursuant to the Lead Manager Mandate.

Securities Subject to Restrictions

The number of the Company's securities subject to ASX restrictions and the restriction period applied to those securities is set out below.

Class	Number	Restriction Period
Ordinary fully paid shares	16,789,351	24 months from the date of official quotation
Ordinary fully paid shares	1,793,250	12 months from the date of issue of the securities – to 30 April 2019
Total Shares	18,582,601	
Options exercisable at \$0.35 each expiring on 31 Dec 2021	5,000,000	24 months from the date of official quotation
Options exercisable at \$0.35 each expiring on 31 Dec 2021	300,000	12 months from the date of issue of the securities – to 17 July 2019
Total Options	5,300,000	
Performance Rights	6,000,000	24 months from the date of official quotation

In addition, the Company notes the following securities are subject to voluntary restrictions and the restriction periods applied to those securities is set out below.

Class	Number	Restriction Period
Ordinary fully paid shares	1,300,000	18 months from the date of official quotation
Options exercisable at \$0.35 each expiring on 31 Dec 2021	1,400,000	24 months from the date of official quotation

Capital Structure

The capital structure of the Company is set out below.

Class	Number
Ordinary fully paid shares	57,578,750
Options exercisable at \$0.35 each expiring on 31 Dec 2021	7,500,000
Performance Rights	6,000,000

For and on behalf of the Company

Emma Waldon
Company Secretary